肿瘤干细胞标记物CD133和EpCAM在子宫内膜癌中的表达及意义  

Expression and Clinicopathologic Significance of the Cancer Stem Cell Markers CD133 and EpCAM in Endometrial Cancer

作　　者：李斌[1] 张志强[1] 盛黎黎[1] 周晟[2] 

机构地区：[1]武警湖北省总队医院病理科,武汉市430061 [2]华中科技大学同济医学院附属同济医院病理研究所

出　　处：《中国肿瘤临床》2012年第17期1281-1284,共4页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金(编号:81072168)资助~~

摘　　要：目的:研究肿瘤干细胞标记物CD133和EpCAM在正常子宫内膜及子宫内膜癌组织中的表达及其临床病理意义。方法:应用免疫组化法检测CD133和EpCAM在65例子宫内膜癌和30例正常增生期子宫内膜组织中的表达情况,并分析其与子宫内膜癌病理分级、临床分期、浸润深度及淋巴结转移等临床病理指标之间的关系。结果:CD133和EpCAM在子宫内膜癌组织中的表达显著高于正常子宫内膜组织(P=0.02,P=0.007),在子宫内膜癌组织中,CD133和EpCAM的表达与肿瘤大小(P=0.006,P=0.007)、组织学分级(P=0.008,P=0.013)、浸润深度(P<0.001,P=0.008)、淋巴结转移(P=0.002,P=0.024)、FIGO分期(P=0.004,P=0.010)均呈显著正相关关系。CD133和EpCAM在子宫内膜癌中的表达呈正相关(r=0.84,P<0.010)。结论:肿瘤干细胞标记物CD133和EpCAM与肿瘤的发生及进展有关,检测其在子宫内膜癌组织中的表达情况有助于预测肿瘤的生物学行为。Objective： To investigate the clinicopathological significances of CD133 and EpCAM expression in endometrial cancer. Methods： CD133 and EpCAM expression were assessed in 65 cases of paraffin-embedded endometrial cancer and 34 cases of normal endometrium tissue by immunohistochemistry. Medical records were reviewed and the clinicopathological characteristics or outcomes were evaluated. Results： CD133 and EpCAM expression was significantly higher in endometrial cancer than in normal endometrium tissue （P = 0.02; P = 0.007）. CD133 and EpCAM were positively correlated with the tumor size （P = 0.006; P -- 0.007）, histological grade （P = 0.008; P = 0.013）, infiltrative depth （P 〈 0.001; P = 0.008）, lymph node metastasis （P = 0.002; P = 0.004）, and International Federation of Gynecology and Obstetrics stage （P = 0.004; P = 0.010）. CD133 and EpCAM expression in endometrial cancer had a positive correlation （r = 0.84, P 〈 0.01）. Conclusion： The overexpression of CD133 and EpCAM is linked to tumor development and progression. Hence, the expression levels of these two proteins are useful indicators for the clinical assessment of tumor biological behavior in patients with endometrial cancer

关 键 词：CD133EpCAM肿瘤干细胞 子宫内膜癌 

分 类 号：R737.33[医药卫生—肿瘤]